戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e or geranylgeranyl pyrophosphate but not by farnesyl pyrophosphate.
2  formed both caryophyllene and humulene from farnesyl pyrophosphate.
3 es, such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate.
4 generated by the sesquiterpene synthase from farnesyl pyrophosphate.
5 oid, geranylgeranyl pyrophosphate and not by farnesyl pyrophosphate.
6 finity labeling with a 32P-labeled analog of farnesyl pyrophosphate.
7 urs) in the absence (control) or presence of farnesyl pyrophosphate (10 muM) or geranylgeranyl pyroph
8       Because of the metabolic importance of farnesyl pyrophosphate, a 15-carbon (C15) intermediate o
9  we designed protein sensors that respond to farnesyl pyrophosphate, a metabolic intermediate in the
10 te and geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, abolished these anticontractile
11                  Statins block production of farnesyl pyrophosphate, an intermediate in the synthesis
12         Enzyme assays have revealed that the farnesyl pyrophosphate analogue is an inhibitor of FTase
13  analyses of cell lysates, indicate that the farnesyl pyrophosphate analogue penetrates the cells as
14 d nonracemic forms, to provide a new type of farnesyl pyrophosphate analogue.
15                        A biomimetic route to farnesyl pyrophosphate and dimethyl orsellinic acid (DMO
16 tidic acid receptor with weaker responses to farnesyl pyrophosphate and geranylgeranyl diphosphate.
17 gly, the levels of the cholesterol precursor farnesyl pyrophosphate and its derivative geranylgeranyl
18 PS-induced iNOS expression by mevalonate and farnesyl pyrophosphate and reversal of the inhibitory ef
19 odel of MS are via depletion of isoprenoids (farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate)
20 rnesol, the natural dephosphorylated form of farnesyl pyrophosphate, and N-acetyl-S-trans,trans-farne
21 including mevalonate, geranyl pyrophosphate, farnesyl pyrophosphate, and ubiquinone, failed to signif
22                       The phosphorylation of farnesyl pyrophosphate appears to occur in vivo as cells
23 nic acid (the product of HMG-coenzyme A) and farnesyl-pyrophosphate but not by geranyl-geranylpyropho
24 y hydroxymethylglutaryl-CoA, mevalonate, and farnesyl pyrophosphate, but not cholesterol and ubiquino
25                       The phosphorylation of farnesyl pyrophosphate by Nm23 proteins could alter isop
26           The phosphorylation of geranyl and farnesyl pyrophosphates by Nm23 proteins provides a nove
27 nidulenes and aspernidines at the expense of farnesyl pyrophosphate-derived austinols provides unexpe
28 gesting that [(3)H]F-OH was incorporated via farnesyl pyrophosphate (F-P-P).
29 l-P), dolichyl pyrophosphate (dolichyl-P-P), farnesyl pyrophosphate (farnesyl-P-P), and geranylgerany
30    We describe the design and synthesis of a farnesyl pyrophosphate (FPP) analogue, 8-anilinogeranyl
31  pyrophosphate (BnPP) series of transferable farnesyl pyrophosphate (FPP) analogues (1a-e) to test th
32 he synthesis of the wound-healing inhibitors farnesyl pyrophosphate (FPP) and cortisol, ligands for t
33 multaneously determine the concentrations of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos
34                              The isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos
35  by depleting mevalonate pathway metabolites farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophos
36 hosphate (FPP) derivatives modified at C7 of farnesyl pyrophosphate (FPP) bearing either a hydroxymet
37 sing the X-ray crystallographic structure of farnesyl pyrophosphate (FPP) bound to the target enzyme,
38 hese events were significantly attenuated by farnesyl pyrophosphate (FPP) but not by geranylgeranyl p
39        Augmentation of the metabolic flux to farnesyl pyrophosphate (FPP) by different FPP synthases
40 of the 15-carbon sterol pathway intermediate farnesyl pyrophosphate (FPP) cause increased Hmg2p ubiqu
41 gal origin, is capable of converting two new farnesyl pyrophosphate (FPP) derivatives modified at C7
42 ructure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat F
43           We apply this approach to regulate farnesyl pyrophosphate (FPP) production in the isoprenoi
44 tes in mevalonate-depleted cells reveal that farnesyl pyrophosphate (FPP) restores Ras processing and
45 STSs) enable cationic cascade reactions with farnesyl pyrophosphate (FPP) resulting in an immense var
46 roposed for the carbocationic cyclization of farnesyl pyrophosphate (FPP) to (+)-aristolochene cataly
47 ules of isopentenyl pyrophosphate (IPP) with farnesyl pyrophosphate (FPP) to generate the C(55) undec
48            We synthesized analogues (3-6) of farnesyl pyrophosphate (FPP) to probe the range of modif
49 se (FPTase) transfers the farnesyl moiety of farnesyl pyrophosphate (FPP) to the thiol of the CaaX bo
50 from geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP) to their protein or peptide
51                                              Farnesyl pyrophosphate (FPP), a key intermediate in the
52                       Here, we discover that farnesyl pyrophosphate (FPP), a metabolic intermediate o
53  of mevalonate or its isoprenoid derivative, farnesyl pyrophosphate (FPP), prevented this increase.
54 te, geranylgeranyl pyrophosphate (GGPP), and farnesyl pyrophosphate (FPP), which are lipids downstrea
55 MEV, squalene and ergosterol, as well as the farnesyl pyrophosphate (FPP)-derived side products farne
56 yzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP).
57 step pathway initiated by C10 methylation of farnesyl pyrophosphate (FPP, C(15) ) along with cyclizat
58 VA), geranylgeranyl-pyrophosphate (GGPP) and farnesyl-pyrophosphate (FPP), all intermediates in the c
59 e inhibitor GGTI-298, and prenyl substrates (farnesyl pyrophosphate [FPP] and geranylgeranyl pyrophos
60 arge number of important molecules including farnesyl pyrophosphate, geranylgeranyl pyrophosphate, ch
61 ived from dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have attracted much biosynthetic
62  from 3,5-dimethylorsellinic acid (DMOA) and farnesyl pyrophosphate have not been reported despite he
63 ct of NaPA on LPS-induced iNOS expression by farnesyl pyrophosphate, however, suggests a role of farn
64 ygeranyl-pyrophosphate is more critical than farnesyl-pyrophosphate in glial cells.
65 derived from geranylgeranyl pyrophosphate or farnesyl pyrophosphate is an essential requisite for cel
66     Wild type Nm23-H1 had higher geranyl and farnesyl pyrophosphate kinase activities than did mutant
67                                      Neither farnesyl pyrophosphate nor squalene inhibited statin-ind
68  or geranylgeranyl-pyrophosphate, but not by farnesyl-pyrophosphate or cholesterol, suggesting that d
69 to a hydroxyl on the pyrophosphate moiety of farnesyl pyrophosphate, pK(a2) = 7.4.
70                      The altered squalene to farnesyl pyrophosphate ratio leading to synthesis of nid
71 duct formation decreases for C3 fluoromethyl farnesyl pyrophosphate substrates, paralleling the numbe
72 ophosphate (FPP) bound to the target enzyme, farnesyl pyrophosphate synthase (FPP synthase), to guide
73 umoral effects through the modulation of the farnesyl pyrophosphate synthase (FPPS) activity.
74  bone-resorption diseases, target osteoclast farnesyl pyrophosphate synthase (FPPS) and inhibit prote
75 that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, p
76 loning and sequencing of a gene encoding the farnesyl pyrophosphate synthase (FPPS) of Trypanosoma br
77 he 5 alpha-halo-analogues potently inhibited farnesyl pyrophosphate synthase (FPPS) with IC50 values
78  be the isoprene biosynthesis pathway enzyme farnesyl pyrophosphate synthase (FPPS), as indicated by
79 rs of the mevalonate/isoprene pathway enzyme farnesyl pyrophosphate synthase (FPPS), we also compared
80 its most firmly established cellular target, farnesyl pyrophosphate synthase (FPPS).
81 ons of the activity of bisphosphonate drugs, farnesyl pyrophosphate synthase (FPPSase) inhibitors, in
82                                        Human farnesyl pyrophosphate synthase (hFPPS) controls intrace
83                                        Human farnesyl pyrophosphate synthase (hFPPS) controls the pos
84                                        Human farnesyl pyrophosphate synthase (hFPPS) is the gate-keep
85                                    The human farnesyl pyrophosphate synthase (hFPPS), a key regulator
86 ine-based allosteric inhibitors of the human farnesyl pyrophosphate synthase (hFPPS), characterized b
87 nthesis are catalyzed by the related enzymes farnesyl pyrophosphate synthase and geranylgeranyl pyrop
88 al roles in cell survival, and inhibition of farnesyl pyrophosphate synthase by nitrogen-containing b
89 ship study of the inhibition of an expressed farnesyl pyrophosphate synthase enzyme by bisphosphonate
90 nomenon strongly augmented by zoledronate, a farnesyl pyrophosphate synthase inhibitor that increases
91 loning and sequencing of a gene encoding the farnesyl pyrophosphate synthase of Trypanosoma cruzi.
92 ntaining bisphosphonate zoledronate inhibits farnesyl pyrophosphate synthase, a key enzyme of the mev
93 ins, including acetyl-CoA acetyltransferase, farnesyl pyrophosphate synthase, and carnitine O-octanoy
94 droxy-3-methylglutaryl coenzyme A reductase, farnesyl pyrophosphate synthase, and cytochrome P-450-51
95 els for HMG-CoA reductase, HMG-CoA synthase, farnesyl pyrophosphate synthase, and squalene synthase,
96 mRNA levels for all of these enzymes, except farnesyl pyrophosphate synthase, indicating a specific l
97                        The protein (T. cruzi farnesyl pyrophosphate synthase, TcFPPS) is an attractiv
98  any, IPP and expressed much lower levels of farnesyl pyrophosphate synthase.
99 it the dimeric organization also observed in farnesyl pyrophosphate synthase.
100 from the chain elongation site described for farnesyl pyrophosphate synthase.
101 lonate/isoprene biosynthesis pathway enzyme, farnesyl pyrophosphate synthase.
102 edronate, in T. b. rhodesiense is the enzyme farnesyl pyrophosphate synthase.
103  stearoyl-CoA desaturase, squalene synthase, farnesyl-pyrophosphate synthase, 3-hydroxy-3-methylgluta
104 e to HMG-CoA reductase (upstream enzyme) and farnesyl-pyrophosphate synthase, respectively.
105  (ODC2) and HT-A/-B genes in the pistil, and farnesyl pyrophosphate synthase2 (FPS2), ui6.2, and ui12
106                                              Farnesyl pyrophosphate synthetase (FPPS) synthesizes far
107                                              Farnesyl pyrophosphate synthetase (FPS; EC 2.5.1.10) pro
108     p13(II) localizes to mitochondria, binds farnesyl pyrophosphate synthetase, an enzyme involved in
109 e isoprenoid biosynthetic pathway leading to farnesyl pyrophosphate, the immediate molecular precurso
110  pyrophosphate synthetase (FPPS) synthesizes farnesyl pyrophosphate through successive condensations
111 A PFT that transfers the farnesyl group from farnesyl pyrophosphate to a cysteine that is 4 residues
112 e gene encoding a phosphatase which converts farnesyl pyrophosphate to farnesol.
113 actions of the universal alicyclic precursor farnesyl pyrophosphate to produce more than 300 differen
114 lium roqueforti catalyzes the cyclization of farnesyl pyrophosphate to the bicyclic sesquiterpene ari
115  Nm23 proteins can phosphorylate geranyl and farnesyl pyrophosphates to give triphosphates.
116 orphologic and cytoskeletal changes, whereas farnesyl pyrophosphate was ineffective.
117 carboxamide ribotide (ZMP), GDP-mannose, and farnesyl pyrophosphate were found to be rapidly altered
118 se (FPS; EC 2.5.1.10) produces the 15-carbon farnesyl pyrophosphate which is utilized in the synthesi

 
Page Top